RxDoctor Payments Data

Marsha di Peppe

Family · Midlothian, VANPI 1154811776

Payments from drug & device makers

$4,615in general payments, 2019–2025

Across 55 payments — averaging $83.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Insulet Corporation$2K
  • Abbott$406
  • Sanofi-aventis U.S. LLC$249
  • Tandem Diabetes Care, Inc.$190
  • Sequel Med Tech, LLC$188
  • plus $243 from 6 others

What the payments were for

  • Travel & lodging$2,12046%
  • Food & beverage$2,49554%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,615 in reported general payments places this provider in the 90th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$74,731
Medicare patients
226
Services billed
2,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide182$281,725
MounjaroTirzepatide126$153,157
JardianceEmpagliflozin138$143,226
TrulicityDulaglutide86$129,374
FarxigaDapagliflozin Propanediol59$63,854
Humalog Kwikpen U-200Insulin Lispro24$56,118
Tresiba Flextouch U-200Insulin Degludec30$52,910
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/741$48,743
RybelsusSemaglutide33$32,343
Tresiba Flextouch U-100Insulin Degludec42$31,007
Synjardy XrEmpagliflozin/Metformin Hcl26$27,145
Humalog Kwikpen U-100Insulin Lispro77$24,822
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$21,865
JanuviaSitagliptin Phosphate29$19,345
Lantus SolostarInsulin Glargine,hum.Rec.Anlog98$17,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$27$318,030229 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$35$294,008256 claims
AstraZenecaFarxiga$126$63,85459 claims
Sanofi-aventis U.S. LLCLantus$249$1,74314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,332 family providers in Virginia.

Other family in Midlothian

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →